Abnormal uterine bleeding

Abnormal uterine bleeding

Abnormal uterine bleeding

On this page

Quick Overview

Abnormal uterine bleeding (AUB) affects 14-25% of reproductive-age women. NICE NG88 provides evidence-based investigation and management pathways. Understanding the PALM-COEIN classification is essential for systematic assessment and appropriate treatment selection, particularly the distinction between structural (PALM) and non-structural (COEIN) causes.

Core Facts & Concepts

Definitions & Thresholds:

  • Heavy menstrual bleeding (HMB): Excessive blood loss interfering with physical, emotional, social, or material quality of life
  • Intermenstrual bleeding (IMB): Bleeding between regular menstrual periods
  • Postcoital bleeding (PCB): Bleeding after sexual intercourse
  • Postmenopausal bleeding (PMB): Any bleeding >12 months after last menstrual period

PALM-COEIN Classification:

Structural (PALM)Non-Structural (COEIN)
PolypCoagulopathy
AdenomyosisOvulatory dysfunction
LeiomyomaEndometrial
Malignancy/hyperplasiaIatrogenic
Not yet classified

Figure 1: Transvaginal ultrasound showing thickened endometrium measuring 16mm

Key Investigation Thresholds (NICE NG88):

  • 📊 Transvaginal USS: First-line structural imaging
  • 📊 Endometrial biopsy indicated if:
    • Age ≥45 years with persistent IMB
    • Treatment failure for HMB
    • Endometrial thickness >12mm postmenopausal
    • Suspected endometrial pathology on imaging

Problem-Solving Approach

NICE NG88 Investigation Pathway:

  1. History & Examination:

    • Impact on quality of life (patient-reported severity)
    • Pattern: cyclical vs irregular, volume, associated symptoms
    • Risk factors: age, obesity, PCOS, family history
    • Cervical screening status
  2. First-line Investigations:

    • Full blood count (exclude anaemia: Hb <120 g/L women)
    • Coagulation screen if HMB since menarche or family history
    • Thyroid function tests if additional symptoms
  3. Imaging Decision Points:

    • 🚩 Always USS if: Palpable pelvic mass, examination difficult/abnormal, pharmaceutical treatment failed
    • Consider hysteroscopy if: Persistent IMB, suspected submucosal fibroids, endometrial polyps
  4. Endometrial Sampling:

    • Pipelle biopsy (outpatient)
    • Hysteroscopy with biopsy if Pipelle inadequate

Figure 2: Hysteroscopy view showing endometrial polyp

🚩 Red Flags: PMB, persistent IMB >45 years, visible cervical lesion, pelvic mass = urgent investigation

Analysis Framework

First-Line Management Options (NICE NG88):

TreatmentMechanismKey FactsFirst Choice When...
Levonorgestrel-IUS (52mg)Endometrial suppression80-90% reduction in blood loss, contraceptiveNo contraindications, wants contraception
Tranexamic acidAntifibrinolytic40-50% reduction, taken during menses onlyPrefers non-hormonal, no structural cause
NSAIDs (mefenamic acid)Prostaglandin synthesis inhibition20-30% reduction, helps dysmenorrhoeaMild HMB with dysmenorrhoea
Combined hormonal contraceptiveEndometrial thinningRegular bleeding patternWants contraception, <40 years

Contraindications to Consider:

  • LNG-IUS: Distorted uterine cavity (>3cm submucous fibroid), active infection, undiagnosed bleeding
  • Tranexamic acid: History of thromboembolism (relative)
  • NSAIDs: Peptic ulcer disease, renal impairment

Visual Aid

Second-Line/Surgical Options:

OptionIndicationsNotes
Endometrial ablationHMB, no structural cause, family complete80% satisfaction, not suitable if >10cm uterus
Hysteroscopic resectionSubmucosal fibroids <3cm, polypsDay case procedure
Uterine artery embolisationSymptomatic fibroidsPreserves uterus
HysterectomyFailed conservative managementDefinitive treatment

Key Points Summary

PALM-COEIN classification: Systematic approach separating structural (PALM) from non-structural (COEIN) causes

NICE NG88 endometrial biopsy indications: Age ≥45 with persistent IMB, treatment failure, endometrial thickness >12mm postmenopausal

First-line pharmaceutical: Levonorgestrel-IUS 52mg (80-90% reduction), tranexamic acid (40-50% reduction), or NSAIDs (20-30% reduction)

USS indications: Palpable mass, abnormal examination, failed pharmaceutical treatment

Red flags requiring urgent investigation: PMB, persistent IMB >45 years, visible cervical lesion, palpable pelvic mass

Patient-centred approach: Impact on quality of life determines treatment need, not objective blood loss measurement

Common pitfall: Forgetting coagulation screen in HMB since menarche (13% have bleeding disorder, most commonly von Willebrand disease)

Practice Questions: Abnormal uterine bleeding

Test your understanding with these related questions

A 30-year-old woman presents with amenorrhea, hirsutism, and acne. She has gained 10kg over the past year. Ultrasound shows multiple ovarian cysts. Testosterone and LH are elevated, FSH is normal. What is the most likely diagnosis?

1 of 5

Flashcards: Abnormal uterine bleeding

1/10

The Risk Malignancy Index (RMI) prognosis in ovarian cancer is based on _____

Hint: 3

TAP TO REVEAL ANSWER

The Risk Malignancy Index (RMI) prognosis in ovarian cancer is based on _____

US findings, Menopausal status, CA125 levels

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial